The recurrence rate of ovarian endometrioma in women aged 40–49 years and impact of hormonal treatment after conservative surgery

article OA: gold CC0 ⤵ 15 in-corpus citations
AI-generated summary by claude@2026-06, 2026-06-08

This retrospective study found that ovarian endometrioma recurred in 8.3% of women aged 40-49 after conservative surgery, with large cyst size being a significant risk factor, and post-operative hormonal treatment did not reduce recurrence.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

AI-generated deep summary by claude@2026-06, 2026-06-10

This retrospective single-center study evaluated recurrence rates and risk factors for ovarian endometrioma after conservative surgery in 408 women aged 40–49, with ≥6 months follow-up using ultrasound-based criteria for recurrence. Among participants, 8.3% (34/408) experienced recurrence, with a median time to recurrence of 22.4 months and cumulative recurrence rates of 3.7% at 12 months, 6.7% at 24 months, 11.1% at 36 months, and 16.7% at 60 months. Recurrence was associated with multilocular cysts, prior surgery for ovarian endometrioma, and prior salpingectomy, while in multivariate analysis only large cyst size (>5.5 cm) remained a risk factor; the authors report that post-operative hormonal medication (types and duration) did not reduce recurrence. This paper is centrally about endometriosis — it analyzes ovarian endometrioma recurrence in women aged 40–49 years after conservative surgery and evaluates the impact of post-operative hormonal treatment.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

The aim of this study was to evaluate the rate of and risk factors for recurrence ovarian endometrioma after conservative surgery in patients aged 40-49 years. This retrospective, single-center study included 408 women between January 2008 and November 2018. All patients underwent ovarian cyst enucleation, were pathologically diagnosed with ovarian endometrioma and were followed up for ≥ 6 months. Recurrence was defined as a cystic mass with diameter ≥ 2 cm detected by sonography. Recurrence rate after conservative surgery and risk factor of recurrence were analyzed. The median follow-up duration after surgery was 32.0 ± 25.9 months (range 6-125 months). Ovarian endometrioma recurred in 34 (8.3%) of included women and median time to recurrence was 22.4 ± 18.2 months. The cumulative recurrences rate at 12, 24, 36, and 60 months were 3.7%, 6.7%, 11.1%, and 16.7%, respectively. Recurrence was correlated with multilocular cysts (p = 0.038), previous surgical history of ovarian endometrioma (p = 0.006) and salpingectomy (p = 0.043), but not use or duration of post-operative medication. In multivariate analysis, large cyst size (> 5.5 cm) was only risk factor for recurrence in this age group. Post-operative medication did not reduce disease recurrence rate, and thus may be administered for endometriosis-associated pain rather than to prevent recurrence in patients aged 40-49 years.

My notes (saved in your browser only)

Condition tags

mesh:D004715endometriosisendometrioma

MeSH descriptors

Endometriosis Neoplasm Recurrence, Local Ovarian Neoplasms Adult Conservative Treatment Conservative Treatment Endometriosis Endometriosis Female Humans Laparoscopy Laparoscopy Middle Aged Neoplasm Recurrence, Local Ovarian Cysts Ovarian Cysts Ovarian Cysts Ovarian Neoplasms Ovarian Neoplasms Retrospective Studies

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (30)

Cited by (15)

Source provenance

europepmc
last seen: 2026-06-04T01:30:01.192114+00:00
openalex
last seen: 2026-06-10T16:23:13.998983+00:00
pubmed
last seen: 2026-05-13T22:21:42.008780+00:00
License: CC0 · commercial use OK